Krystal Biotech (KRYS) Research & Development (2016 - 2026)

Krystal Biotech has reported Research & Development for 11 years, with the latest figure at $14.5 million in Q2 2026.

• Research & Development for Q2 2026 came in at $14.5 million, up 0.75% year-over-year; the trailing twelve-month figure through Jun 2026 was $59.2 million (up 6.32% YoY), and the FY2025 annual result was $58.0 million, up 8.33% from the prior year.
• Research & Development declined to $14.5 million in Q2 2026, from $15.3 million in the prior quarter.
• Over five years, Research & Development peaked at $15.6 million in Q2 2024 and troughed at $9.3 million in Q1 2022.
• A 5-year average of $12.8 million and a median of $12.9 million in 2023 frame the typical range for Research & Development.
• The widest annual swing landed in 2022, when Research & Development jumped 89.41%; it then slipped 10.83% in 2024.
• A 5-year view of Research & Development shows it stood at $10.7 million in 2022, then increased by 5.87% to $11.4 million in 2023, then grew by 18.96% to $13.5 million in 2024, then grew by 9.36% to $14.8 million in 2025, then dropped by 1.87% to $14.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $14.5 million in Q2 2026, $15.3 million in Q1 2026, and $14.8 million in Q4 2025.